Effects of captopril and icatibant on bradykinin (BK) and des[Arg9]BK in carrageenan-induced edema

Peptides

Volumn 17, Issue 6, 1996, Pages 1009-1015

  Décarie, Anick ^a   Adam, Albert ^a   Couture, Réjean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

angiotensin converting enzyme; B2 kinin receptor; bradykinin; captopril; Hoe 140; inflammation

Indexed keywords

BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ RECEPTOR; CAPTOPRIL; CARRAGEENAN; DIPEPTIDYL CARBOXYPEPTIDASE; ICATIBANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; EDEMA; INFLAMMATION; INTRADERMAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0029855363     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(96)00145-3     Document Type: Article

References (38)

1. 1. Bao, G.; Qadri, F.; Stauss, B.; Stauss, H.; Gohlke, P.; Unger, T. HOE 140, a new highly potent and long-acting bradykinin antagonist in conscious rats. Eur. J. Pharmacol. 200:179-182; 1991.
2. 2. Bhoola, K. D.; Figueroa, C. D.; Worthy, K. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol. Rev. 44(1):1-80; 1992.
3. 3. Burch, R. M.; DeHass, C. A bradykinin antagonist inhibits carrageenan edema in rats. Naunyn Schmiedebergs Arch. Pharmacol. 342:189-193; 1990.
4. 4. Campbell, D. J.; Kladis, A.; Duncan, A.-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 23:439-449; 1994.
5. 2 receptors in bradykinin-induced rat paw oedema. Br. J. Pharmacol. 114:1005-1013; 1995.
6. 6. Damas, J.; Remacle-Volon, G. Influence of a long-acting bradykinin antagonist, Hoe 140, on some acute inflammatory reactions in the rat. Eur. J. Pharmacol. 211:81-86; 1992.
7. 7. Décarie, A.; Drapeau, G.; Closset, J.; Couture, R.; Adam, A. Development of digoxigenin-labeled peptide: Application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues. Peptides 15(3):511-518; 1994.
8. 9]BK: Influence of enalaprilat. Am. J. Physiol. (in press).
9. 9. Dray, A.; Perkins, M. Bradykinin and inflammatory pain. Trends Neurosci. 16:99-104; 1993.
10. 10. Dray, A.; Bevan, S. Inflammation and hyperalgesia: Highlighting the team effort. Trends Pharmacol. Sci. 14(8):287-290; 1993.
11. 11. Erdös, E. G. Some old and some new ideas on kinin metabolism. J. Cardiovasc. Pharmacol. 15(Suppl. 6):S20-S24; 1990.
12. 12. Gamillscheg, A.; Holzer, P.; Donnerer, J.; Lembeck, F. Effect of neonatal treatment with capsaicin on carrageenan-induced paw oedema in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 326:340-342; 1984.
13. 13. Geppetti, P. Sensory neuropeptide release by bradykinin: Mechanisms and pathophysiological implications. Regul. Pept. 47:1-23; 1993.
14. 14. Gilligan, J. P.: Lovato, S. J.; Erion, M. D.; Jeng, A. Y. Modulation of carrageenan-induced hind paw edema by substance P. Inflammation 18(3):285-292; 1994.
15. 15. Griswold, D. E.; Alessi, S.; Webb, E. F.; Walz, D. T. Inhibition of carrageenan-induced inflammation by urethan anesthesia in adrenalectomized and sham-operated rats. J. Pharmacol. Methods 8:161-164; 1982.
16. 16. Hall, J. M. Bradykinin receptors: Pharmacological properties and biological roles. Pharmacol. Ther. 56:131-190; 1992.
17. 17. Hall, J. M.; Hallet, C. A simple precise method for measuring rodent paw volume. J. Pharm. Pharmacol. 27:623; 1975.
18. 18. Hargreaves, K. M.; Troullos, E. S.; Dionne, R. A.; Schmidt, E. A.; Schafer, S. C.; Joris, J. L. Bradykinin is increased during acute and chronic inflammation: Therapeutic implications. Clin. Pharmacol. Ther. 44:613-621; 1988.
19. 19. Hock, F. J.; Wirth, K.; Albus, U.; Linz, W.; Gerhards, H. J.; Wiemer, G.; Henke, St.; Breipohl, G.; König, W.; Knolle, J.; Schölkens, B. A. Hoe 140 a new potent and long acting bradykinin-antagonist: In vitro studies. Br. J. Pharmacol. 102:769-773; 1991.
20. 20. Izzo, A. A.; Mascolo, N.; Di Urno, M. V.; Autore, G.; Di Carlo, G.; Capasso, F. Platelet activating factor potentiates rat paw oedema induced by different phlogogen agents. Agents Actions 41:140-143; 1994.
21. 21. Kozin, F.; Cochrane, C. G. Contact activation system of plasma. Biochemistry and pathophysiology. In: Gallin, J. I.; Goldstein, I. M.; Snyderman, R., Eds. Inflammation: Basic principles and clinical correlates. Second edition. New York: Raven Press; 1992:103-121.
22. 22. Labrecque, G.; Doré, F.; Bélanger, P.-M. Circadian variation of carrageenan-paw edema in the rat. Life Sci. 28:1337-1343; 1981.
23. 23. Linz, W.; Wiemer, G.; Gohlke, P.; Unger, T.; Schölkens, B. A. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47(1):25-49; 1995.
24. 24. Loubaris, N.; Cros, G.; Serrano, J. J.; Boucard, M. Circadian and circannual variation of the carregeenin inflammatory effect in rat. Life Sci. 32:1349-1354; 1983.
25. 25. Marceau, F.; Lussier, A.; Regoli, D.; Giroud, J. P. Pharmacology of kinins: Their relevance to tissue injury and inflammation. Gen. Pharmacol. 14(2):209-229; 1983.
26. 1, receptors: A review. Immunopharmacology 30:1-26; 1995.
27. 9]BK in plasma. Can. J. Physiol. Pharmacol. 59:131-138; 1981.
28. 2 receptor stimulation and is potentiated by concomitantly released prostaglandins. Acta Physiol. Scand. 142:141-147; 1991.
29. 29. Otterness, I. G.; Moore, P. F. Carrageenan foot edema test. Methods Enzymol. 162:320-327; 1988.
30. 8]-BK and HOE 140, in two models of persistent hyperalgesia in the rat. Pain 53:191-197; 1993.
31. 9-bradykinin using a chemiluminescence enzyme immunoassay: Application to its kinetic profile during plasma activation. J. Immunol. Methods 180:247-257; 1995.
32. 32. Regoli, D.; Barabé, J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32:1-46; 1980.
33. 8]bradykinin). Eur. J. Pharmacol. 210:115-120; 1992.
34. 34. Skidgel, R. A. Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J. Cardiovasc. Pharmacol. 20(Suppl. 9):S4-S9; 1992.
35. 35. Winter, C. A.; Risley, E. A.; Nuss, G. W. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. 111:544-547; 1962.
36. 36. Wirth, K.; Hock, F. J.; Albus, U.; Linz, W.; Alpermann, H. G.; Anagnostopoulos, H.; Henke, St.; Breipohl, G.; König, W.; Knolle, J.; Schölkens, B. A. Hoe 140 a new potent and long-acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol. 102:774-777; 1991.
37. 37. Wirth, K.; Alperman, H. G.; Satoh, R.; Inazu, M. The bradykinin antagonist Hoe 140 inhibits carrageenan and thermically induced paw oedema in rats. Agents Actions Suppl. 38:428-431; 1992.
38. 38. Yong, T.; Gao, X. P.; Koizumi, S.; Conlon, J. M.; Rennard, S. I.; Mayhan, W. G.; Rubinstein, I. Role of peptidases in bradykinin-induced increase in vascular permeability in vivo. Circ. Res. 70:952-959; 1992.